Compare Merck & Co., Inc. (MRK) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Merck & Co., Inc. trades at $150.05 (market cap $350.29B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.26B). The key difference: Merck & Co., Inc. is far larger — about 278× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| MRK | USAS | |
|---|---|---|
Market Cap | $350.29B | $1.26B |
Volume | 8,158,912 | 3,948,671 |
Sector | Health | Basic Materials |
52-Week High | $156.43 | $10.03 |
52-Week Low | $82.49 | $3.59 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $1.19B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.
The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
